Agentix (AGTX) Notes Payables (2017 - 2023)

Agentix's (AGTX) quarterly Notes Payables came in at $50000.0 in Q1 2023, down 96.29% on a QoQ basis from $1.3 million in Q4 2022.

Agentix (AGTX) Notes Payables (2017 - 2023) Analysis & Trends

Agentix (AGTX) has 7 years of Notes Payables data on file, last reported at $50000.0 in Q1 2023.

Quarterly Notes Payables changed N/A year-over-year to $50000.0 in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $50000.0 (changed N/A YoY) and the FY2023 annual result came in at $50000.0, down 94.72% from the prior year.
Notes Payables fell to $50000.0 in Q1 2023, from $1.3 million in the prior quarter.
In the past five years, Notes Payables ranged from a high of $1.3 million in Q4 2022 to a low of $5250.0 in Q4 2019.
A 5-year average of $428204.2 and a median of $77300.0 in 2021 frame the typical range for Notes Payables.
Annual changes were most pronounced in 2019 — Notes Payables sank 56.22% — and 2021, when it surged 1825.69%.
Tracing AGTX's Notes Payables over 5 years: stood at $5250.0 in 2019, then soared by 545.2% to $33873.0 in 2020, then surged by 1825.69% to $652289.0 in 2021, then surged by 106.86% to $1.3 million in 2022, then tumbled by 96.29% to $50000.0 in 2023.
The last three Notes Payables figures came in at $50000.0 (Q1 2023), $1.3 million (Q4 2022), and $1.2 million (Q3 2022), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.90 Bn	131.05 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.10 Bn	78.11 Bn	3.93 Bn
3	Argenx Se	65.56 Bn	60.37 Bn	1.37 Bn
4	Moderna	55.82 Bn	50.68 Bn	52.00 Mn
5	BeOne Medicines	42.14 Bn	37.04 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.67 Bn	28.36 Bn	992.69 Mn
7	BioNTech SE	27.74 Bn	9.35 Bn	668.28 Mn
8	Insmed	27.53 Bn	26.37 Bn	358.27 Mn
9	Royalty Pharma	27.38 Bn	26.54 Bn	-
10	Agentix	801,339.00	801,301.00	-

Download Data